US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the ADHD Therapeutics market. Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the ADHD Therapeutics market." Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers. The global ADHD Therapeutics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on ADHD Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall ADHD Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered: Eli Lilly Novartis Shire Pfizer GlaxoSmithKline Mallinckrodt Pharmaceuticals Hisamitsu Pharmaceutical Impax Laboratories Johnson & Johnson UCB S.A. Purdue Parma Segment by Regions North America Europe China Japan Segment by Type Stimulants Non-stimulants Segment by Application Specialty Clinics Hospital Pharmacies Retail Pharmacies E-Commerce
Table of Contents Executive Summary 1 ADHD Therapeutics Market Overview 1.1 Product Overview and Scope of ADHD Therapeutics 1.2 ADHD Therapeutics Segment by Type 1.2.1 Global ADHD Therapeutics Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Stimulants 1.2.3 Non-stimulants 1.3 ADHD Therapeutics Segment by Application 1.3.1 ADHD Therapeutics Consumption Comparison by Application (2014-2025) 1.3.2 Specialty Clinics 1.3.3 Hospital Pharmacies 1.3.4 Retail Pharmacies 1.3.5 E-Commerce 1.4 Global ADHD Therapeutics Market by Region 1.4.1 Global ADHD Therapeutics Market Size Region 1.4.2 North America Status and Prospect (2014-2025) 1.4.3 Europe Status and Prospect (2014-2025) 1.4.4 China Status and Prospect (2014-2025) 1.4.5 Japan Status and Prospect (2014-2025) 1.5 Global ADHD Therapeutics Market Size 1.5.1 Global ADHD Therapeutics Revenue (2014-2025) 1.5.2 Global ADHD Therapeutics Production (2014-2025) 2 Global ADHD Therapeutics Market Competition by Manufacturers 2.1 Global ADHD Therapeutics Production Market Share by Manufacturers (2014-2019) 2.2 Global ADHD Therapeutics Revenue Share by Manufacturers (2014-2019) 2.3 Global ADHD Therapeutics Average Price by Manufacturers (2014-2019) 2.4 Manufacturers ADHD Therapeutics Production Sites, Area Served, Product Types 2.5 ADHD Therapeutics Market Competitive Situation and Trends 2.5.1 ADHD Therapeutics Market Concentration Rate 2.5.2 ADHD Therapeutics Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global ADHD Therapeutics Production Market Share by Regions 3.1 Global ADHD Therapeutics Production Market Share by Regions 3.2 Global ADHD Therapeutics Revenue Market Share by Regions (2014-2019) 3.3 Global ADHD Therapeutics Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North America ADHD Therapeutics Production 3.4.1 North America ADHD Therapeutics Production Growth Rate (2014-2019) 3.4.2 North America ADHD Therapeutics Production, Revenue, Price and Gross Margin (2014-2019) 3.5 Europe ADHD Therapeutics Production ... | read more...